Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG)’s share price reached a new 52-week low on Thursday . The stock traded as low as $0.98 and last traded at $0.98, with a volume of 552,940 shares trading hands. The stock had previously closed at $1.12.

Several equities analysts have recently weighed in on the stock. HC Wainwright set a $6.00 target price on shares of Eyegate Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday. Noble Financial reissued a “buy” rating on shares of Eyegate Pharmaceuticals in a report on Friday, May 19th.

The company’s market capitalization is $17.03 million. The company has a 50 day moving average of $1.32 and a 200 day moving average of $1.86.

Eyegate Pharmaceuticals (NASDAQ:EYEG) last released its earnings results on Monday, May 8th. The specialty pharmaceutical company reported ($0.39) EPS for the quarter, meeting analysts’ consensus estimates of ($0.39). Eyegate Pharmaceuticals had a negative return on equity of 840.69% and a negative net margin of 1,737.29%. The company had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.22 million. On average, equities research analysts expect that Eyegate Pharmaceuticals, Inc. will post ($1.24) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This news story was first published by Daily Political and is the property of of Daily Political. If you are viewing this news story on another website, it was stolen and reposted in violation of United States & international trademark & copyright law. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/08/10/eyegate-pharmaceuticals-inc-eyeg-hits-new-1-year-low-at-0-98.html.

About Eyegate Pharmaceuticals

Eyegate Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.

Receive News & Ratings for Eyegate Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.